[1]
Balduini CL. The name counts: the case of 'congenital amegakaryocytic thrombocytopenia'. Haematologica. 2023 May 1:108(5):1216-1219. doi: 10.3324/haematol.2022.282024. Epub 2023 May 1
[PubMed PMID: 36226496]
Level 3 (low-level) evidence
[2]
Maserati E, Panarello C, Morerio C, Valli R, Pressato B, Patitucci F, Tassano E, Di Cesare-Merlone A, Cugno C, Balduini CL, Lo Curto F, Dufour C, Locatelli F, Pasquali F. Clonal chromosome anomalies and propensity to myeloid malignancies in congenital amegakaryocytic thrombocytopenia (OMIM 604498). Haematologica. 2008 Aug:93(8):1271-3. doi: 10.3324/haematol.12748. Epub 2008 Jun 2
[PubMed PMID: 18519517]
[3]
Khincha PP, Savage SA. Neonatal manifestations of inherited bone marrow failure syndromes. Seminars in fetal & neonatal medicine. 2016 Feb:21(1):57-65. doi: 10.1016/j.siny.2015.12.003. Epub 2015 Dec 24
[PubMed PMID: 26724991]
[4]
Al-Qahtani FS. Congenital amegakaryocytic thrombocytopenia: a brief review of the literature. Clinical medicine insights. Pathology. 2010 Jun 4:3():25-30
[PubMed PMID: 21151552]
[5]
Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Seminars in thrombosis and hemostasis. 2011 Sep:37(6):673-81. doi: 10.1055/s-0031-1291377. Epub 2011 Nov 18
[PubMed PMID: 22102270]
[6]
Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematology/oncology and stem cell therapy. 2019 Jun:12(2):115-118. doi: 10.1016/j.hemonc.2017.09.001. Epub 2018 Jan 31
[PubMed PMID: 29409729]
[7]
Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R. "Almost bleeding to death": the conundrum of acquired amegakaryocytic thrombocytopenia. Case reports in hematology. 2014:2014():806541. doi: 10.1155/2014/806541. Epub 2014 Feb 6
[PubMed PMID: 24649385]
[8]
Chaudhary UB, Eberwine SF, Hege KM. Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course. American journal of hematology. 2004 Mar:75(3):146-50
[PubMed PMID: 14978695]
[9]
Geddis AE. Congenital amegakaryocytic thrombocytopenia. Pediatric blood & cancer. 2011 Aug:57(2):199-203. doi: 10.1002/pbc.22927. Epub 2011 Feb 18
[PubMed PMID: 21337678]
[10]
Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematology/oncology clinics of North America. 2009 Apr:23(2):321-31. doi: 10.1016/j.hoc.2009.01.012. Epub
[PubMed PMID: 19327586]
[11]
Wang S, Yang X, Ai Y, Zhu Y. Haploidentical Hematopoietic Stem Cell Transplantation in a 3-Year-Old Girl with Congenital Amegakaryocytic Thrombocytopenia: A Case Report. Klinische Padiatrie. 2022 Nov:234(6):388-390. doi: 10.1055/a-1933-2583. Epub 2022 Nov 15
[PubMed PMID: 36379227]
Level 3 (low-level) evidence
[12]
Varghese LN, Defour JP, Pecquet C, Constantinescu SN. The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin. Frontiers in endocrinology. 2017:8():59. doi: 10.3389/fendo.2017.00059. Epub 2017 Mar 31
[PubMed PMID: 28408900]
[13]
Pecci A, Ragab I, Bozzi V, De Rocco D, Barozzi S, Giangregorio T, Ali H, Melazzini F, Sallam M, Alfano C, Pastore A, Balduini CL, Savoia A. Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim. EMBO molecular medicine. 2018 Jan:10(1):63-75. doi: 10.15252/emmm.201708168. Epub
[PubMed PMID: 29191945]
[14]
Germeshausen M, Ancliff P, Estrada J, Metzler M, Ponstingl E, Rütschle H, Schwabe D, Scott RH, Unal S, Wawer A, Zeller B, Ballmaier M. MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia. Blood advances. 2018 Mar 27:2(6):586-596. doi: 10.1182/bloodadvances.2018016501. Epub
[PubMed PMID: 29540340]
Level 3 (low-level) evidence
[15]
Azuno Y, Yaga K. Successful cyclosporin A therapy for acquired amegakaryocytic thrombocytopenic purpura. American journal of hematology. 2002 Apr:69(4):298-9
[PubMed PMID: 11921030]
[16]
Mulroy E, Gleeson S, Chiruka S. Danazol: an effective option in acquired amegakaryocytic thrombocytopaenic purpura. Case reports in hematology. 2015:2015():171253. doi: 10.1155/2015/171253. Epub 2015 Apr 5
[PubMed PMID: 25945269]
Level 3 (low-level) evidence
[17]
Evans DI. Immune amegakaryocytic thrombocytopenia of the newborn: association with anti-HLA-A2. Journal of clinical pathology. 1987 Mar:40(3):258-61
[PubMed PMID: 3494047]
[18]
Khan F, Shehna A, Mukundan L. Mononeuritis multiplex in acquired amegakaryocytic thrombocytopenia. Journal of neurosciences in rural practice. 2015 Oct-Dec:6(4):588-90. doi: 10.4103/0976-3147.165351. Epub
[PubMed PMID: 26752909]
[19]
Ichikawa T, Shimojima Y, Otuki T, Ueno KI, Kishida D, Sekijima Y. Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease: Successful Combination Therapy with Tocilizumab and Cyclosporine. Internal medicine (Tokyo, Japan). 2019 Dec 1:58(23):3473-3478. doi: 10.2169/internalmedicine.2929-19. Epub 2019 Aug 6
[PubMed PMID: 31391399]
[20]
Manoharan A, Williams NT, Sparrow R. Acquired amegakaryocytic thrombocytopenia: report of a case and review of literature. The Quarterly journal of medicine. 1989 Mar:70(263):243-52
[PubMed PMID: 2690174]
Level 3 (low-level) evidence
[21]
Dahal S, Sharma E, Dahal S, Shrestha B, Bhattarai B. Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia in Thymoma. Case reports in hematology. 2018:2018():5034741. doi: 10.1155/2018/5034741. Epub 2018 Mar 11
[PubMed PMID: 29713553]
Level 3 (low-level) evidence
[22]
Ikeda N, Hisano Y, Kamao T, Uno M, Mizushima T. Acquired Amegakaryocytic Thrombocytopenia Associated With Autoimmune Hemolytic Anemia. Cureus. 2022 Jul:14(7):e27315. doi: 10.7759/cureus.27315. Epub 2022 Jul 26
[PubMed PMID: 36042987]
[23]
Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM. Acquired amegakaryocytic thrombocytopenic purpura. American journal of hematology. 2006 Feb:81(2):132-5
[PubMed PMID: 16432869]
[24]
Ergas D, Tsimanis A, Shtalrid M, Duskin C, Berrebi A. T-gamma large granular lymphocyte leukemia associated with amegakaryocytic thrombocytopenic purpura, Sjögren's syndrome, and polyglandular autoimmune syndrome type II, with subsequent development of pure red cell aplasia. American journal of hematology. 2002 Feb:69(2):132-4
[PubMed PMID: 11835350]
[25]
Savoia A, Dufour C, Locatelli F, Noris P, Ambaglio C, Rosti V, Zecca M, Ferrari S, di Bari F, Corcione A, Di Stazio M, Seri M, Balduini CL. Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica. 2007 Sep:92(9):1186-93
[PubMed PMID: 17666371]
[26]
Novotný JP, Köhler B, Max R, Egerer G. Acquired Amegakaryocytic Thrombocytopenic Purpura Progressing into Aplastic Anemia. Prague medical report. 2017:118(4):147-155. doi: 10.14712/23362936.2017.16. Epub
[PubMed PMID: 29324222]
[28]
Kim AR, Sankaran VG. Thrombopoietin: tickling the HSC's fancy. EMBO molecular medicine. 2018 Jan:10(1):10-12. doi: 10.15252/emmm.201708450. Epub
[PubMed PMID: 29191946]
[29]
Hirata S, Takayama N, Jono-Ohnishi R, Endo H, Nakamura S, Dohda T, Nishi M, Hamazaki Y, Ishii E, Kaneko S, Otsu M, Nakauchi H, Kunishima S, Eto K. Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. The Journal of clinical investigation. 2013 Sep:123(9):3802-14. doi: 10.1172/JCI64721. Epub 2013 Aug 1
[PubMed PMID: 23908116]
[30]
Ok Bozkaya İ, Yaralı N, Işık P, Ünsal Saç R, Tavil B, Tunç B. Severe Clinical Course in a Patient with Congenital Amegakaryocytic Thrombocytopenia Due to a Missense Mutation of the c-MPL Gene. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2015 Jun:32(2):172-4. doi: 10.4274/tjh.2013.0191. Epub
[PubMed PMID: 26316487]
[31]
Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proceedings of the National Academy of Sciences of the United States of America. 1999 Mar 16:96(6):3132-6
[PubMed PMID: 10077649]
[32]
Nishino S, Kodaka T, Sawada Y, Goka T, Gotoh Y, Tsunemine H, Takahashi T. Marked rebound thrombocytosis in response to glucocorticoids in a patient with acquired amegakaryocytic thrombocytopenia. Journal of clinical and experimental hematopathology : JCEH. 2018 Dec 13:58(4):166-170. doi: 10.3960/jslrt.18016. Epub 2018 Nov 9
[PubMed PMID: 30416171]
[33]
Katsumata Y, Suzuki T, Kuwana M, Hattori Y, Akizuki S, Sugiura H, Matsuoka Y. Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. Arthritis and rheumatism. 2003 Jun:48(6):1647-51
[PubMed PMID: 12794833]
[34]
Ichimata S, Kobayashi M, Honda K, Shibata S, Matsumoto A, Kanno H. Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection. World journal of gastroenterology. 2017 Sep 21:23(35):6540-6545. doi: 10.3748/wjg.v23.i35.6540. Epub
[PubMed PMID: 29085203]
[35]
Germeshausen M, Ballmaier M. CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients. Haematologica. 2021 Sep 1:106(9):2439-2448. doi: 10.3324/haematol.2020.257972. Epub 2021 Sep 1
[PubMed PMID: 32703794]
[36]
Obi EI, Osegi N, Etu-Efeotor TP, Pughikumo OC, Toluhi H, Makinde O. Massive hemoperitoneum from hemorrhagic corpus luteum in a patient with acquired amegakaryocytic thrombocytopenic purpura. Clinical case reports. 2020 Apr:8(4):719-721. doi: 10.1002/ccr3.2767. Epub 2020 Mar 7
[PubMed PMID: 32274044]
Level 3 (low-level) evidence
[37]
Ballmaier M, Holter W, Germeshausen M. Flow cytometric detection of MPL (CD110) as a diagnostic tool for differentiation of congenital thrombocytopenias. Haematologica. 2015 Sep:100(9):e341-4. doi: 10.3324/haematol.2015.125963. Epub 2015 Apr 24
[PubMed PMID: 25911549]
[38]
Oved JH, Shah YB, Venella K, Paessler ME, Olson TS. Non-myeloablative conditioning is sufficient to achieve complete donor myeloid chimerism following matched sibling donor bone marrow transplant for myeloproliferative leukemia virus oncogene (MPL) mutation-driven congenital amegakaryocytic thrombocytopenia: Case report. Frontiers in pediatrics. 2022:10():903872. doi: 10.3389/fped.2022.903872. Epub 2022 Jul 28
[PubMed PMID: 35967582]
Level 3 (low-level) evidence
[39]
Cancio M, Hebert K, Kim S, Aljurf M, Olson T, Anderson E, Burroughs L, Vatsayan A, Myers K, Hashem H, Hanna R, Horn B, Prestidge T, Boelens JJ, Boulad F, Eapen M. Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplantation and cellular therapy. 2022 Feb:28(2):101.e1-101.e6. doi: 10.1016/j.jtct.2021.10.009. Epub 2021 Oct 17
[PubMed PMID: 34670170]
[40]
Cleyrat C, Girard R, Choi EH, Jeziorski É, Lavabre-Bertrand T, Hermouet S, Carillo S, Wilson BS. Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia. Blood advances. 2017 Sep 26:1(21):1815-1826. doi: 10.1182/bloodadvances.2016002915. Epub 2017 Sep 22
[PubMed PMID: 29296828]
Level 3 (low-level) evidence
[41]
Fox NE, Lim J, Chen R, Geddis AE. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents. Experimental hematology. 2010 May:38(5):384-91. doi: 10.1016/j.exphem.2010.02.007. Epub 2010 Feb 24
[PubMed PMID: 20188141]
Level 2 (mid-level) evidence
[42]
Dragani M, Andreani G, Familiari U, Marci V, Rege-Cambrin G. Pure red cell aplasia and amegakaryocytic thrombocytopenia in thymoma: The uncharted territory. Clinical case reports. 2020 Apr:8(4):598-601. doi: 10.1002/ccr3.2642. Epub 2020 Mar 17
[PubMed PMID: 32274018]
Level 3 (low-level) evidence
[43]
Katai M, Aizawa T, Ohara N, Hiramatsu K, Hashizume K, Yamada T, Kitano K, Saito H, Shinoda T, Wakata S. Acquired amegakaryocytic thrombocytopenic purpura with humoral inhibitory factor for megakaryocyte colony formation. Internal medicine (Tokyo, Japan). 1994 Mar:33(3):147-9
[PubMed PMID: 8061390]
[44]
Lonial S, Bilodeau PA, Langston AA, Lewis C, Mossavi-Sai S, Holden JT, Waller EK. Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature. Bone marrow transplantation. 1999 Dec:24(12):1337-41
[PubMed PMID: 10627644]
Level 3 (low-level) evidence
[45]
Hussain SA, Fatima H, Faisal H, Bansal M. Acquired Amegakaryocytic Thrombocytopenia Progressing to Aplastic Anaemia. European journal of case reports in internal medicine. 2022:9(9):003479. doi: 10.12890/2022_003479. Epub 2022 Sep 5
[PubMed PMID: 36299833]
Level 3 (low-level) evidence
[46]
Gupta L, Gupta V, Pani KC, Mittal N, Agarwal V. Successful use of azathioprine in glucocorticoid refractory immune amegakaryocytic thrombocytopenia of lupus. Reumatologia clinica. 2020 May-Jun:16(3):249-250. doi: 10.1016/j.reuma.2018.03.005. Epub 2018 Apr 17
[PubMed PMID: 29678667]
[47]
Tu X, Xue A, Wu S, Jin M, Zhao P, Zhang H. Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia. Frontiers in pharmacology. 2021:12():795884. doi: 10.3389/fphar.2021.795884. Epub 2022 Jan 27
[PubMed PMID: 35153753]
Level 3 (low-level) evidence
[48]
Ammeti D, Marzollo A, Gabelli M, Zanchetta ME, Tretti-Parenzan C, Bottega R, Capaci V, Biffi A, Savoia A, Bresolin S, Faleschini M. A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure. British journal of haematology. 2023 Dec:203(5):852-859. doi: 10.1111/bjh.19023. Epub 2023 Aug 23
[PubMed PMID: 37610030]
[49]
Capaci V, Adam E, Bar-Joseph I, Faleschini M, Pecci A, Savoia A. Defective binding of ETS1 and STAT4 due to a mutation in the promoter region of THPO as a novel mechanism of congenital amegakaryocytic thrombocytopenia. Haematologica. 2023 May 1:108(5):1385-1393. doi: 10.3324/haematol.2022.281392. Epub 2023 May 1
[PubMed PMID: 36226497]
[50]
Xue Y, Wu Q, Pu D, Xu F, Li Y. Radiation‑induced pure red cell aplasia combined with acquired amegakaryocytic thrombocytopenia in a thymoma after rapid response to radiotherapy: A case report and literature review. Experimental and therapeutic medicine. 2023 May:25(5):237. doi: 10.3892/etm.2023.11936. Epub 2023 Apr 4
[PubMed PMID: 37114181]
Level 3 (low-level) evidence